Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSR-N-ab
- Development stage
- Preclinical
- Modality
- Antibody-Based Therapeutics
- Administration
- In Vitro
01
Overview
LSR-N-ab is an antibody directed against the extracellular N-terminal domain of the human lipolysis-stimulated lipoprotein receptor (LSR), a protein involved in regulation of epithelial barrier function via tricellular tight junctions. LSR-N-ab disrupts epithelial integrity, increases paracellular permeability, and induces apoptosis in endometrial endometrioid carcinoma (EEC) cells, primarily through modulation of signaling pathways such as JNK and Pyk2. It is being explored as a potential therapeutic to enhance chemotherapy or directly induce apoptosis in LSR-expressing cancers, especially EEC[1][3].
- Other names
- anti-LSR-N-terminal antibody
02
Targets
LSR (Lipolysis-stimulated lipoprotein receptor)
Beyond the preview
Go deeper on LSR-N-ab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSR-N-ab.